Clinical Trial Update: A Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Pembrolizumab (SB27, EU Sourced Keytruda, and US Sourced Keytruda) in Subjects With Stage II-IIIA NSCLC Following Complete Resection and Adjuvant Platinum-based Chemotherapy [Phase 1]

View source ↗

Summary

Phase 1 trial comparing pharmacokinetics, efficacy, safety, and immunogenicity of the pembrolizumab biosimilar SB27 versus EU/US-sourced pembrolizumab (Keytruda…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Pembrolizumab (Keytruda) (pembrolizumab)
• SB27 (pembrolizumab biosimilar)

Snippet

Sponsor: Samsung Bioepis Co., Ltd. | Conditions: Non-small Cell Lung Cancer Stage II, Non-small Cell Lung Cancer Stage IIIA | Phase 1 | Status: ACTIVE_NOT_RECRUITING